All In Biotech

Drug Trial Radar · NCT02425644

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,133 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,133

Actual

Start

Jun 4, 2015

Primary completion

May 16, 2019

Study completion May 16, 2019

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis

Conditions

  • Multiple Sclerosis

Interventions

  • ponesimodDrug

    film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning

  • teriflunomideDrug

    film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Confirmed Relapse RateTime frame: From randomization to end of study (Week 108)

Locations

162 sites in 28 countries. Site status is shown where the registry gives one.

  • Investigator Site 8045

    Carlsbad, California

  • Investigator Site 8311

    Pomona, California

  • Investigator Site 8036

    Denver, Colorado

  • Investigator Site 8065

    Ormond Beach, Florida

  • Investigator Site 8018

    Tampa, Florida

  • Investigator Site 8013

    Indianapolis, Indiana

  • Investigator Site 8040

    Raleigh, North Carolina

  • Investigator Site 8006

    Columbus, Ohio

  • Investigator Site 8015

    Franklin, Tennessee

  • Investigator Site 8042

    Orem, Utah

  • Investigator Site 3605

    Grodno, Belarus

  • Investigator Site 3603

    Minsk, Belarus

  • Investigator Site 3602

    Minsk, Belarus

  • Investigator Site 3606

    Vitebsk, Belarus

  • Investigator Site 3604

    Vitebsk, Belarus

  • Investigator Site 9104

    Sarajevo, Bosnia and Herzegovina

  • Investigator Site 2709

    Plovdiv, Bulgaria

  • Investigator Site 2711

    Sofia, Bulgaria

  • Investigator Site 2702

    Sofia, Bulgaria

  • Investigator Site 2707

    Sofia, Bulgaria

  • Investigator Site 2701

    Sofia, Bulgaria

  • Investigator Site 2708

    Sofia, Bulgaria

  • Investigator Site 2703

    Sofia, Bulgaria

  • Investigator Site 8102

    Edmonton, Alberta, Canada

  • Investigator Site 8120

    Victoria, British Columbia, Canada

  • Investigator Site 8101

    Ottawa, Ontario, Canada

  • Investigator Site 8113

    Greenfield Park, Quebec, Canada

  • Investigator Site 2506

    Osijek, Croatia

  • Investigator Site 2502

    Zagreb, Croatia

  • Investigator Site 2508

    Zagreb, Croatia

  • Investigator Site 2509

    Zagreb, Croatia

  • Investigator Site 3009

    Brno, Czechia

  • Investigator Site 3003

    Brno, Czechia

  • Investigator Site 3010

    Hradec Králové, Czechia

  • Investigator Site 3006

    Jihlava, Czechia

  • Investigator Site 3002

    Ostrava-Poruba, Czechia

  • Investigator Site 3007

    Pardubice, Czechia

  • Investigator Site 3001

    Prague, Czechia

  • Investigator Site 3008

    Prague, Czechia

  • Investigator Site 3004

    Teplice, Czechia

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.